ID   TGM2_HUMAN              Reviewed;         687 AA.
AC   P21980; E1P5V9; Q16436; Q6B838; Q9BTN7; Q9H035; Q9UH35;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 2.
DT   28-JUN-2023, entry version 236.
DE   RecName: Full=Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305};
DE            EC=2.3.2.13 {ECO:0000269|PubMed:23941696, ECO:0000269|PubMed:24349085, ECO:0000269|PubMed:31991788};
DE   AltName: Full=Erythrocyte transglutaminase {ECO:0000303|PubMed:2903073};
DE   AltName: Full=Heart G alpha(h) {ECO:0000303|PubMed:7592956};
DE            Short=hhG alpha(h) {ECO:0000303|PubMed:7592956};
DE   AltName: Full=Isopeptidase TGM2 {ECO:0000305};
DE            EC=3.4.-.- {ECO:0000269|PubMed:26250429, ECO:0000269|PubMed:27131890};
DE   AltName: Full=Protein G alpha(h) {ECO:0000303|PubMed:8943303};
DE            Short=G(h) {ECO:0000303|PubMed:8943303};
DE   AltName: Full=Protein-glutamine deamidase TGM2 {ECO:0000305};
DE            EC=3.5.1.44 {ECO:0000269|PubMed:20547769, ECO:0000269|PubMed:9623982};
DE   AltName: Full=Protein-glutamine dopaminyltransferase TGM2 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:32273471};
DE   AltName: Full=Protein-glutamine histaminyltransferase TGM2 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:23797785};
DE   AltName: Full=Protein-glutamine noradrenalinyltransferase TGM2 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000250|UniProtKB:P08587};
DE   AltName: Full=Protein-glutamine serotonyltransferase TGM2 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:30867594};
DE   AltName: Full=Tissue transglutaminase {ECO:0000303|PubMed:1358880, ECO:0000303|PubMed:1670766, ECO:0000303|PubMed:7935379, ECO:0000303|PubMed:9212111};
DE            Short=tTG {ECO:0000303|PubMed:7935379, ECO:0000303|PubMed:9212111};
DE            Short=tTgase {ECO:0000303|PubMed:12506096, ECO:0000303|PubMed:7649299};
DE   AltName: Full=Transglutaminase C {ECO:0000303|PubMed:11390390};
DE            Short=TG(C) {ECO:0000303|PubMed:11390390};
DE            Short=TGC {ECO:0000303|PubMed:11390390};
DE            Short=TGase C {ECO:0000303|PubMed:11390390};
DE   AltName: Full=Transglutaminase H {ECO:0000303|PubMed:1358880};
DE            Short=TGase H {ECO:0000303|PubMed:1358880};
DE   AltName: Full=Transglutaminase II {ECO:0000303|PubMed:7592956};
DE            Short=TGase II {ECO:0000303|PubMed:7592956};
DE   AltName: Full=Transglutaminase-2 {ECO:0000303|PubMed:24349085, ECO:0000303|PubMed:30458214};
DE            Short=TG2 {ECO:0000303|PubMed:24349085, ECO:0000303|PubMed:30458214};
DE            Short=TGase-2;
DE            Short=hTG2 {ECO:0000303|PubMed:28858494};
GN   Name=TGM2 {ECO:0000303|PubMed:17939176, ECO:0000312|HGNC:HGNC:11778};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Endothelial cell;
RX   PubMed=1670766; DOI=10.1016/s0021-9258(18)52460-1;
RA   Gentile V., Saydak M., Chiocca E.A., Akande O., Birckbichler P.J.,
RA   Lee K.N., Stein J.P., Davies P.J.A.;
RT   "Isolation and characterization of cDNA clones to mouse macrophage and
RT   human endothelial cell tissue transglutaminases.";
RL   J. Biol. Chem. 266:478-483(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INDUCTION.
RX   PubMed=1358880; DOI=10.1016/s0021-9258(18)41717-6;
RA   Fraij B.M., Birckbichler P.J., Patterson M.K. Jr., Lee K.N., Gonzales R.A.;
RT   "A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a
RT   novel tissue transglutaminase homologue.";
RL   J. Biol. Chem. 267:22616-22623(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=8611626; DOI=10.1016/0167-4781(95)00219-7;
RA   Fraij B.M., Gonzales R.A.;
RT   "A third human tissue transglutaminase homologue as a result of alternative
RT   gene transcripts.";
RL   Biochim. Biophys. Acta 1306:63-74(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Colon adenocarcinoma;
RA   Bayardo M.P., de Urraza P., Chirdo F.G.;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-76; HIS-214; ARG-324;
RP   TRP-436 AND SER-536.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-9; 365-377; 565-590; 635-649 AND 664-674, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 448-548 (ISOFORM 2).
RC   TISSUE=Lymph node;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [12]
RP   ACTIVITY REGULATION.
RX   PubMed=2903073; DOI=10.1016/0014-5793(88)80928-1;
RA   Bergamini C.M.;
RT   "GTP modulates calcium binding and cation-induced conformational changes in
RT   erythrocyte transglutaminase.";
RL   FEBS Lett. 239:255-258(1988).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1683874; DOI=10.1002/jcp.1041490304;
RA   Upchurch H.F., Conway E., Patterson M.K. Jr., Maxwell M.D.;
RT   "Localization of cellular transglutaminase on the extracellular matrix
RT   after wounding: characteristics of the matrix bound enzyme.";
RL   J. Cell. Physiol. 149:375-382(1991).
RN   [14]
RP   FUNCTION.
RX   PubMed=7935379; DOI=10.1128/mcb.14.10.6584-6596.1994;
RA   Melino G., Annicchiarico-Petruzzelli M., Piredda L., Candi E., Gentile V.,
RA   Davies P.J., Piacentini M.;
RT   "Tissue transglutaminase and apoptosis: sense and antisense transfection
RT   studies with human neuroblastoma cells.";
RL   Mol. Cell. Biol. 14:6584-6596(1994).
RN   [15]
RP   FUNCTION, ACTIVE SITE, AND MUTAGENESIS OF CYS-277.
RX   PubMed=7649299; DOI=10.1016/0014-5793(95)00782-5;
RA   Mian S., el Alaoui S., Lawry J., Gentile V., Davies P.J., Griffin M.;
RT   "The importance of the GTP-binding protein tissue transglutaminase in the
RT   regulation of cell cycle progression.";
RL   FEBS Lett. 370:27-31(1995).
RN   [16]
RP   FUNCTION, INTERACTION WITH PHOSPHOLIPASE C, AND MUTAGENESIS OF
RP   665-VAL--LYS-672.
RX   PubMed=7592956; DOI=10.1074/jbc.270.45.27058;
RA   Hwang K.C., Gray C.D., Sivasubramanian N., Im M.J.;
RT   "Interaction site of GTP binding Gh (transglutaminase II) with
RT   phospholipase C.";
RL   J. Biol. Chem. 270:27058-27062(1995).
RN   [17]
RP   FUNCTION, ACTIVE SITE, AND MUTAGENESIS OF CYS-277.
RX   PubMed=8943303; DOI=10.1074/jbc.271.50.32385;
RA   Chen S., Lin F., Iismaa S., Lee K.N., Birckbichler P.J., Graham R.M.;
RT   "Alpha1-adrenergic receptor signaling via Gh is subtype specific and
RT   independent of its transglutaminase activity.";
RL   J. Biol. Chem. 271:32385-32391(1996).
RN   [18]
RP   FUNCTION.
RX   PubMed=9252372; DOI=10.1074/jbc.272.33.20577;
RA   Nemes Z. Jr., Adany R., Balazs M., Boross P., Fesues L.;
RT   "Identification of cytoplasmic actin as an abundant glutaminyl substrate
RT   for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis.";
RL   J. Biol. Chem. 272:20577-20583(1997).
RN   [19]
RP   IDENTIFICATION AS AUTOANTIGEN OF CELIAC DISEASE.
RX   PubMed=9212111; DOI=10.1038/nm0797-797;
RA   Dieterich W., Ehnis T., Bauer M., Donner P., Volta U., Riecken E.O.,
RA   Schuppan D.;
RT   "Identification of tissue transglutaminase as the autoantigen of celiac
RT   disease.";
RL   Nat. Med. 3:797-801(1997).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9575137; DOI=10.1074/jbc.273.20.11991;
RA   Lesort M., Attanavanich K., Zhang J., Johnson G.V.;
RT   "Distinct nuclear localization and activity of tissue transglutaminase.";
RL   J. Biol. Chem. 273:11991-11994(1998).
RN   [21]
RP   IDENTIFICATION AS AUTOANTIGEN OF CELIAC DISEASE, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=9623982; DOI=10.1038/nm0698-713;
RA   Molberg O., Mcadam S.N., Koerner R., Quarsten H., Kristiansen C.,
RA   Madsen L., Fugger L., Scott H., Noren O., Roepstorff P., Lundin K.E.,
RA   Sjoestroem H., Sollid L.M.;
RT   "Tissue transglutaminase selectively modifies gliadin peptides that are
RT   recognized by gut-derived T cells in celiac disease.";
RL   Nat. Med. 4:713-717(1998).
RN   [22]
RP   IDENTIFICATION.
RX   PubMed=11390390; DOI=10.1074/jbc.m102553200;
RA   Grenard P., Bates M.K., Aeschlimann D.;
RT   "Evolution of transglutaminase genes: identification of a transglutaminase
RT   gene cluster on human chromosome 15q15. Structure of the gene encoding
RT   transglutaminase X and a novel gene family member, transglutaminase Z.";
RL   J. Biol. Chem. 276:33066-33078(2001).
RN   [23]
RP   FUNCTION (ISOFORM 2), SUBCELLULAR LOCATION (ISOFORM 2), SUBUNIT (ISOFORM
RP   2), MUTAGENESIS OF CYS-277 (ISOFORM 2), AND MUTAGENESIS OF SER-171.
RX   PubMed=17116873; DOI=10.1073/pnas.0604844103;
RA   Antonyak M.A., Jansen J.M., Miller A.M., Ly T.K., Endo M., Cerione R.A.;
RT   "Two isoforms of tissue transglutaminase mediate opposing cellular fates.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18609-18614(2006).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, DISULFIDE
RP   BONDS, AND MUTAGENESIS OF CYS-230; CYS-370 AND CYS-371.
RX   PubMed=20547769; DOI=10.1074/jbc.m109.097162;
RA   Stamnaes J., Pinkas D.M., Fleckenstein B., Khosla C., Sollid L.M.;
RT   "Redox regulation of transglutaminase 2 activity.";
RL   J. Biol. Chem. 285:25402-25409(2010).
RN   [25]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12506096; DOI=10.1167/iovs.02-0224;
RA   Priglinger S.G., May C.A., Neubauer A.S., Alge C.S., Schoenfeld C.L.,
RA   Kampik A., Welge-Lussen U.;
RT   "Tissue transglutaminase as a modifying enzyme of the extracellular matrix
RT   in PVR membranes.";
RL   Invest. Ophthalmol. Vis. Sci. 44:355-364(2003).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [28]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23797785; DOI=10.1007/s00726-013-1532-y;
RA   Lai T.S., Greenberg C.S.;
RT   "Histaminylation of fibrinogen by tissue transglutaminase-2 (TGM-2):
RT   potential role in modulating inflammation.";
RL   Amino Acids 45:857-864(2013).
RN   [29]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF VAL-224.
RX   PubMed=23941696; DOI=10.1042/bj20130696;
RA   Kanchan K., Erguelen E., Kiraly R., Simon-Vecsei Z., Fuxreiter M.,
RA   Fesues L.;
RT   "Identification of a specific one amino acid change in recombinant human
RT   transglutaminase 2 that regulates its activity and calcium sensitivity.";
RL   Biochem. J. 455:261-272(2013).
RN   [30]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   CYS-277.
RX   PubMed=24349085; DOI=10.1371/journal.pone.0081516;
RA   Hsieh Y.F., Liu G.Y., Lee Y.J., Yang J.J., Sandor K., Sarang Z., Bononi A.,
RA   Pinton P., Tretter L., Szondy Z., Tsay G.J.;
RT   "Transglutaminase 2 contributes to apoptosis induction in Jurkat T cells by
RT   modulating Ca2+ homeostasis via cross-linking RAP1GDS1.";
RL   PLoS ONE 8:e81516-e81516(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   FUNCTION, AND MUTAGENESIS OF TRP-180; TRP-241; CYS-277; TRP-278; TRP-332;
RP   PHE-334; TRP-337 AND TYR-516.
RX   PubMed=26250429; DOI=10.1007/s00726-015-2063-5;
RA   Kiraly R., Thangaraju K., Nagy Z., Collighan R., Nemes Z., Griffin M.,
RA   Fesues L.;
RT   "Isopeptidase activity of human transglutaminase 2: disconnection from
RT   transamidation and characterization by kinetic parameters.";
RL   Amino Acids 48:31-40(2016).
RN   [33]
RP   FUNCTION.
RX   PubMed=27131890; DOI=10.1016/j.ab.2016.04.012;
RA   Thangaraju K., Biri B., Schlosser G., Kiss B., Nyitray L., Fesues L.,
RA   Kiraly R.;
RT   "Real-time kinetic method to monitor isopeptidase activity of
RT   transglutaminase 2 on protein substrate.";
RL   Anal. Biochem. 505:36-42(2016).
RN   [34]
RP   REVIEW.
RX   PubMed=27270573; DOI=10.1007/s00726-016-2270-8;
RA   Lai T.S., Lin C.J., Greenberg C.S.;
RT   "Role of tissue transglutaminase-2 (TG2)-mediated aminylation in biological
RT   processes.";
RL   Amino Acids 49:501-515(2017).
RN   [35]
RP   ACTIVITY REGULATION.
RX   PubMed=28858494; DOI=10.1021/acs.jmedchem.7b01070;
RA   Akbar A., McNeil N.M.R., Albert M.R., Ta V., Adhikary G., Bourgeois K.,
RA   Eckert R.L., Keillor J.W.;
RT   "Structure-activity relationships of potent, targeted covalent inhibitors
RT   that abolish both the transamidation and GTP binding activities of human
RT   tissue transglutaminase.";
RL   J. Med. Chem. 60:7910-7927(2017).
RN   [36]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=29618516; DOI=10.1074/jbc.ra117.001078;
RA   Willis W.L., Wang L., Wada T.T., Gardner M., Abdouni O., Hampton J.,
RA   Valiente G., Young N., Ardoin S., Agarwal S., Freitas M.A., Wu L.C.,
RA   Jarjour W.N.;
RT   "The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and
RT   forms high-molecular weight complexes with autoantigens.";
RL   J. Biol. Chem. 293:8394-8409(2018).
RN   [37]
RP   FUNCTION, AND MUTAGENESIS OF CYS-277.
RX   PubMed=30458214; DOI=10.1016/j.bbamcr.2018.11.009;
RA   Maeda A., Nishino T., Matsunaga R., Yokoyama A., Suga H., Yagi T.,
RA   Konishi H.;
RT   "Transglutaminase-mediated cross-linking of WDR54 regulates EGF receptor-
RT   signaling.";
RL   Biochim. Biophys. Acta 1866:285-295(2019).
RN   [38]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30867594; DOI=10.1038/s41586-019-1024-7;
RA   Farrelly L.A., Thompson R.E., Zhao S., Lepack A.E., Lyu Y., Bhanu N.V.,
RA   Zhang B., Loh Y.E., Ramakrishnan A., Vadodaria K.C., Heard K.J.,
RA   Erikson G., Nakadai T., Bastle R.M., Lukasak B.J., Zebroski H. III,
RA   Alenina N., Bader M., Berton O., Roeder R.G., Molina H., Gage F.H.,
RA   Shen L., Garcia B.A., Li H., Muir T.W., Maze I.;
RT   "Histone serotonylation is a permissive modification that enhances TFIID
RT   binding to H3K4me3.";
RL   Nature 567:535-539(2019).
RN   [39]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=32273471; DOI=10.1126/science.aaw8806;
RA   Lepack A.E., Werner C.T., Stewart A.F., Fulton S.L., Zhong P.,
RA   Farrelly L.A., Smith A.C.W., Ramakrishnan A., Lyu Y., Bastle R.M.,
RA   Martin J.A., Mitra S., O'Connor R.M., Wang Z.J., Molina H., Turecki G.,
RA   Shen L., Yan Z., Calipari E.S., Dietz D.M., Kenny P.J., Maze I.;
RT   "Dopaminylation of histone H3 in ventral tegmental area regulates cocaine
RT   seeking.";
RL   Science 368:197-201(2020).
RN   [40] {ECO:0007744|PDB:1KV3}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) IN COMPLEX WITH GDP.
RX   PubMed=11867708; DOI=10.1073/pnas.042454899;
RA   Liu S., Cerione R.A., Clardy J.;
RT   "Structural basis for the guanine nucleotide-binding activity of tissue
RT   transglutaminase and its regulation of transamidation activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2743-2747(2002).
RN   [41] {ECO:0007744|PDB:2Q3Z}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), FUNCTION, ACTIVITY REGULATION, AND
RP   COFACTOR.
RX   PubMed=18092889; DOI=10.1371/journal.pbio.0050327;
RA   Pinkas D.M., Strop P., Brunger A.T., Khosla C.;
RT   "Transglutaminase 2 undergoes a large conformational change upon
RT   activation.";
RL   PLoS Biol. 5:E327-E327(2007).
RN   [42] {ECO:0007744|PDB:3LY6}
RP   X-RAY CRYSTALLOGRAPHY (3.14 ANGSTROMS) IN COMPLEX WITH ATP, AND DISULFIDE
RP   BOND.
RX   PubMed=20450932; DOI=10.1016/j.ijbiomac.2010.04.023;
RA   Han B.G., Cho J.W., Cho Y.D., Jeong K.C., Kim S.Y., Lee B.I.;
RT   "Crystal structure of human transglutaminase 2 in complex with adenosine
RT   triphosphate.";
RL   Int. J. Biol. Macromol. 47:190-195(2010).
RN   [43] {ECO:0007744|PDB:4PYG}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) IN COMPLEX WITH GTP, SUBUNIT, AND
RP   DISULFIDE BOND.
RX   PubMed=25192068; DOI=10.1371/journal.pone.0107005;
RA   Jang T.H., Lee D.S., Choi K., Jeong E.M., Kim I.G., Kim Y.W., Chun J.N.,
RA   Jeon J.H., Park H.H.;
RT   "Crystal structure of transglutaminase 2 with GTP complex and amino acid
RT   sequence evidence of evolution of GTP binding site.";
RL   PLoS ONE 9:e107005-e107005(2014).
RN   [44] {ECO:0007744|PDB:6A8P}
RP   X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) IN COMPLEX WITH GTP.
RX   PubMed=30321187; DOI=10.1371/journal.pone.0204707;
RA   Ha H.J., Kwon S., Jeong E.M., Kim C.M., Lee K.B., Kim I.G., Park H.H.;
RT   "Structure of natural variant transglutaminase 2 reveals molecular basis of
RT   gaining stability and higher activity.";
RL   PLoS ONE 13:e0204707-e0204707(2018).
RN   [45] {ECO:0007744|PDB:6KZB}
RP   X-RAY CRYSTALLOGRAPHY (3.35 ANGSTROMS) IN COMPLEX WITH CALCIUM AND GDP,
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, COFACTOR, AND
RP   MUTAGENESIS OF GLU-437 AND GLU-539.
RX   PubMed=31991788; DOI=10.3390/ijms21030791;
RA   Jeong E.M., Lee K.B., Kim G.E., Kim C.M., Lee J.H., Kim H.J., Shin J.W.,
RA   Kwon M.A., Park H.H., Kim I.G.;
RT   "Competitive binding of magnesium to calcium binding sites reciprocally
RT   regulates transamidase and GTP hydrolysis activity of transglutaminase 2.";
RL   Int. J. Mol. Sci. 21:0-0(2020).
RN   [46]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-660.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [47]
RP   VARIANTS ARG-330 AND ASN-331.
RX   PubMed=17939176; DOI=10.1002/humu.9511;
RA   Porzio O., Massa O., Cunsolo V., Colombo C., Malaponti M., Bertuzzi F.,
RA   Hansen T., Johansen A., Pedersen O., Meschi F., Terrinoni A., Melino G.,
RA   Federici M., Decarlo N., Menicagli M., Campani D., Marchetti P.,
RA   Ferdaoussi M., Froguel P., Federici G., Vaxillaire M., Barbetti F.;
RT   "Missense mutations in the TGM2 gene encoding transglutaminase 2 are found
RT   in patients with early-onset type 2 diabetes.";
RL   Hum. Mutat. 28:1150-1150(2007).
CC   -!- FUNCTION: Calcium-dependent acyltransferase that catalyzes the
CC       formation of covalent bonds between peptide-bound glutamine and various
CC       primary amines, such as gamma-amino group of peptide-bound lysine, or
CC       mono- and polyamines, thereby producing cross-linked or aminated
CC       proteins, respectively (PubMed:9252372, PubMed:23941696,
CC       PubMed:31991788). Involved in many biological processes, such as bone
CC       development, angiogenesis, wound healing, cellular differentiation,
CC       chromatin modification and apoptosis (PubMed:1683874, PubMed:7935379,
CC       PubMed:9252372, PubMed:27270573). Acts as a protein-glutamine gamma-
CC       glutamyltransferase by mediating the cross-linking of proteins, such as
CC       ACO2, HSPB6, FN1, HMGB1, RAP1GDS1, SLC25A4/ANT1, SPP1 and WDR54
CC       (PubMed:23941696, PubMed:24349085, PubMed:29618516, PubMed:30458214).
CC       Under physiological conditions, the protein cross-linking activity is
CC       inhibited by GTP; inhibition is relieved by Ca(2+) in response to
CC       various stresses (PubMed:7649299, PubMed:7592956, PubMed:18092889).
CC       When secreted, catalyzes cross-linking of proteins of the extracellular
CC       matrix, such as FN1 and SPP1 resulting in the formation of scaffolds
CC       (PubMed:12506096). Plays a key role during apoptosis, both by (1)
CC       promoting the cross-linking of cytoskeletal proteins resulting in
CC       condensation of the cytoplasm, and by (2) mediating cross-linking
CC       proteins of the extracellular matrix, resulting in the irreversible
CC       formation of scaffolds that stabilize the integrity of the dying cells
CC       before their clearance by phagocytosis, thereby preventing the leakage
CC       of harmful intracellular components (PubMed:7935379, PubMed:9252372).
CC       In addition to protein cross-linking, can use different monoamine
CC       substrates to catalyze a vast array of protein post-translational
CC       modifications: mediates aminylation of serotonin, dopamine,
CC       noradrenaline or histamine into glutamine residues of target proteins
CC       to generate protein serotonylation, dopaminylation, noradrenalinylation
CC       or histaminylation, respectively (PubMed:23797785, PubMed:30867594).
CC       Mediates protein serotonylation of small GTPases during activation and
CC       aggregation of platelets, leading to constitutive activation of these
CC       GTPases (By similarity). Plays a key role in chromatin organization by
CC       mediating serotonylation and dopaminylation of histone H3
CC       (PubMed:30867594, PubMed:32273471). Catalyzes serotonylation of 'Gln-5'
CC       of histone H3 (H3Q5ser) during serotonergic neuron differentiation,
CC       thereby facilitating transcription (PubMed:30867594). Acts as a
CC       mediator of neurotransmission-independent role of nuclear dopamine in
CC       ventral tegmental area (VTA) neurons: catalyzes dopaminylation of 'Gln-
CC       5' of histone H3 (H3Q5dop), thereby regulating relapse-related
CC       transcriptional plasticity in the reward system (PubMed:32273471).
CC       Regulates vein remodeling by mediating serotonylation and subsequent
CC       inactivation of ATP2A2/SERCA2 (By similarity). Also acts as a protein
CC       deamidase by mediating the side chain deamidation of specific glutamine
CC       residues of proteins to glutamate (PubMed:9623982, PubMed:20547769).
CC       Catalyzes specific deamidation of protein gliadin, a component of wheat
CC       gluten in the diet (PubMed:9623982). May also act as an isopeptidase
CC       cleaving the previously formed cross-links (PubMed:26250429,
CC       PubMed:27131890). Also able to participate in signaling pathways
CC       independently of its acyltransferase activity: acts as a signal
CC       transducer in alpha-1 adrenergic receptor-mediated stimulation of
CC       phospholipase C-delta (PLCD) activity and is required for coupling
CC       alpha-1 adrenergic agonists to the stimulation of phosphoinositide
CC       lipid metabolism (PubMed:8943303). {ECO:0000250|UniProtKB:P08587,
CC       ECO:0000250|UniProtKB:P21981, ECO:0000269|PubMed:12506096,
CC       ECO:0000269|PubMed:1683874, ECO:0000269|PubMed:18092889,
CC       ECO:0000269|PubMed:20547769, ECO:0000269|PubMed:23797785,
CC       ECO:0000269|PubMed:23941696, ECO:0000269|PubMed:24349085,
CC       ECO:0000269|PubMed:26250429, ECO:0000269|PubMed:27131890,
CC       ECO:0000269|PubMed:29618516, ECO:0000269|PubMed:30458214,
CC       ECO:0000269|PubMed:30867594, ECO:0000269|PubMed:31991788,
CC       ECO:0000269|PubMed:32273471, ECO:0000269|PubMed:7592956,
CC       ECO:0000269|PubMed:7649299, ECO:0000269|PubMed:7935379,
CC       ECO:0000269|PubMed:8943303, ECO:0000269|PubMed:9252372,
CC       ECO:0000269|PubMed:9623982, ECO:0000303|PubMed:27270573}.
CC   -!- FUNCTION: [Isoform 2]: Has cytotoxic activity: is able to induce
CC       apoptosis independently of its acyltransferase activity.
CC       {ECO:0000269|PubMed:17116873}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutaminyl-[protein] + L-lysyl-[protein] = [protein]-L-
CC         lysyl-N(6)-5-L-glutamyl-[protein] + NH4(+); Xref=Rhea:RHEA:54816,
CC         Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:10207, Rhea:RHEA-COMP:14005,
CC         ChEBI:CHEBI:28938, ChEBI:CHEBI:29969, ChEBI:CHEBI:30011,
CC         ChEBI:CHEBI:138370; EC=2.3.2.13; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10024, ECO:0000269|PubMed:23941696,
CC         ECO:0000269|PubMed:24349085, ECO:0000269|PubMed:31991788};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54817;
CC         Evidence={ECO:0000269|PubMed:23941696, ECO:0000269|PubMed:24349085,
CC         ECO:0000269|PubMed:31991788};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutaminyl-[protein] + serotonin = 5-serotonyl-L-glutamyl-
CC         [protein] + NH4(+); Xref=Rhea:RHEA:66552, Rhea:RHEA-COMP:10207,
CC         Rhea:RHEA-COMP:17052, ChEBI:CHEBI:28938, ChEBI:CHEBI:30011,
CC         ChEBI:CHEBI:167174, ChEBI:CHEBI:350546;
CC         Evidence={ECO:0000269|PubMed:30867594};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66553;
CC         Evidence={ECO:0000269|PubMed:30867594};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dopamine + L-glutaminyl-[protein] = 5-dopaminyl-L-glutamyl-
CC         [protein] + NH4(+); Xref=Rhea:RHEA:66556, Rhea:RHEA-COMP:10207,
CC         Rhea:RHEA-COMP:17053, ChEBI:CHEBI:28938, ChEBI:CHEBI:30011,
CC         ChEBI:CHEBI:59905, ChEBI:CHEBI:167175;
CC         Evidence={ECO:0000269|PubMed:32273471};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66557;
CC         Evidence={ECO:0000269|PubMed:32273471};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=histamine + L-glutaminyl-[protein] = 5-histaminyl-L-glutamyl-
CC         [protein] + NH4(+); Xref=Rhea:RHEA:66564, Rhea:RHEA-COMP:10207,
CC         Rhea:RHEA-COMP:17056, ChEBI:CHEBI:28938, ChEBI:CHEBI:30011,
CC         ChEBI:CHEBI:58432, ChEBI:CHEBI:167179;
CC         Evidence={ECO:0000269|PubMed:23797785};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66565;
CC         Evidence={ECO:0000269|PubMed:23797785};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-noradrenaline + L-glutaminyl-[protein] = 5-(R)-
CC         noradrenalinyl-L-glutamyl-[protein] + NH4(+); Xref=Rhea:RHEA:66560,
CC         Rhea:RHEA-COMP:10207, Rhea:RHEA-COMP:17054, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:30011, ChEBI:CHEBI:72587, ChEBI:CHEBI:167178;
CC         Evidence={ECO:0000250|UniProtKB:P08587};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66561;
CC         Evidence={ECO:0000250|UniProtKB:P08587};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + L-glutaminyl-[protein] = L-glutamyl-[protein] + NH4(+);
CC         Xref=Rhea:RHEA:16441, Rhea:RHEA-COMP:10207, Rhea:RHEA-COMP:10208,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:28938, ChEBI:CHEBI:29973,
CC         ChEBI:CHEBI:30011; EC=3.5.1.44;
CC         Evidence={ECO:0000269|PubMed:20547769, ECO:0000269|PubMed:9623982};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16442;
CC         Evidence={ECO:0000269|PubMed:20547769, ECO:0000269|PubMed:9623982};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:31991788, ECO:0000305|PubMed:18092889};
CC   -!- ACTIVITY REGULATION: Acyltransferase activity is regulated by the
CC       binding of GTP and Ca(2+): inactivated by GTP, which stabilizes its
CC       closed structure, thereby obstructing the accessibility of substrates
CC       to the active sites (PubMed:2903073, PubMed:7592956, PubMed:18092889,
CC       PubMed:31991788). In contrast, Ca(2+) acts as a cofactor by inducing
CC       conformational change to the active open form (PubMed:2903073,
CC       PubMed:18092889, PubMed:31991788). In absence of Ca(2+), Mg(2+) may
CC       bind Ca(2+)-binding sites, promoting GTP-binding and subsequent
CC       inhibition of the acyltransferase activity (PubMed:31991788).
CC       Specifically inhibited by compound VA4 ((S)-Benzyl (6-Acrylamido-1-(4-
CC       ((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)-1-oxohexan-
CC       2-yl)carbamate), which specifically abolishes both the transamidation
CC       and GTP-binding activities (PubMed:28858494).
CC       {ECO:0000269|PubMed:18092889, ECO:0000269|PubMed:28858494,
CC       ECO:0000269|PubMed:2903073, ECO:0000269|PubMed:31991788,
CC       ECO:0000269|PubMed:7592956}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=11.2 mM for benzyloxycarbonyl-Gln-Gly (for protein-glutamine
CC         deamidase activity) {ECO:0000269|PubMed:20547769};
CC         Note=kcat is 11.2 min(-1) with benzyloxycarbonyl-Gln-Gly substrate
CC         for protein-glutamine deamidase activity.
CC         {ECO:0000269|PubMed:20547769};
CC   -!- SUBUNIT: Monomer (PubMed:25192068). Interacts with phospholipase C;
CC       promoting alpha-1 adrenergic receptor signaling (PubMed:7592956).
CC       Interacts with PLCD1 (By similarity). {ECO:0000250|UniProtKB:Q9WVJ6,
CC       ECO:0000269|PubMed:25192068, ECO:0000269|PubMed:7592956}.
CC   -!- SUBUNIT: [Isoform 2]: Homooligomer. {ECO:0000269|PubMed:17116873}.
CC   -!- INTERACTION:
CC       P21980; Q12802: AKAP13; NbExp=4; IntAct=EBI-727668, EBI-1373806;
CC       P21980; PRO_0000000092 [P05067]: APP; NbExp=2; IntAct=EBI-727668, EBI-821758;
CC       P21980; PRO_0000005794 [P39060]: COL18A1; NbExp=2; IntAct=EBI-727668, EBI-2566375;
CC       P21980; P02751: FN1; NbExp=4; IntAct=EBI-727668, EBI-1220319;
CC       P21980; P08727: KRT19; NbExp=2; IntAct=EBI-727668, EBI-742756;
CC       P21980; PRO_0000018520 [P28300]: LOX; NbExp=3; IntAct=EBI-727668, EBI-20724846;
CC       P21980; Q04206: RELA; NbExp=3; IntAct=EBI-727668, EBI-73886;
CC       P21980; P40337: VHL; NbExp=10; IntAct=EBI-727668, EBI-301246;
CC       P21980-2; G5E9A7: DMWD; NbExp=3; IntAct=EBI-25842075, EBI-10976677;
CC       P21980-2; O00429-3: DNM1L; NbExp=3; IntAct=EBI-25842075, EBI-6896746;
CC       P21980-2; P50570-2: DNM2; NbExp=3; IntAct=EBI-25842075, EBI-10968534;
CC       P21980-2; P29692-2: EEF1D; NbExp=3; IntAct=EBI-25842075, EBI-5280572;
CC       P21980-2; Q06787-7: FMR1; NbExp=3; IntAct=EBI-25842075, EBI-25856644;
CC       P21980-2; P04792: HSPB1; NbExp=3; IntAct=EBI-25842075, EBI-352682;
CC       P21980-2; P42858: HTT; NbExp=6; IntAct=EBI-25842075, EBI-466029;
CC       P21980-2; O60333-2: KIF1B; NbExp=3; IntAct=EBI-25842075, EBI-10975473;
CC       P21980-2; D3DTS7: PMP22; NbExp=3; IntAct=EBI-25842075, EBI-25882629;
CC       P21980-2; P60891: PRPS1; NbExp=3; IntAct=EBI-25842075, EBI-749195;
CC       P21980-2; Q5T160: RARS2; NbExp=3; IntAct=EBI-25842075, EBI-1050546;
CC       P21980-2; Q8N488: RYBP; NbExp=3; IntAct=EBI-25842075, EBI-752324;
CC       P21980-2; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-25842075, EBI-745901;
CC       P21980-2; O95416: SOX14; NbExp=3; IntAct=EBI-25842075, EBI-9087806;
CC       P21980-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-25842075, EBI-5235340;
CC       P21980-2; O14656-2: TOR1A; NbExp=3; IntAct=EBI-25842075, EBI-25847109;
CC       P21980-2; Q86WV8: TSC1; NbExp=3; IntAct=EBI-25842075, EBI-12806590;
CC       P21980-2; P02766: TTR; NbExp=3; IntAct=EBI-25842075, EBI-711909;
CC       P21980-2; Q9NYH9: UTP6; NbExp=3; IntAct=EBI-25842075, EBI-749211;
CC       P21980-2; O76024: WFS1; NbExp=3; IntAct=EBI-25842075, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:24349085,
CC       ECO:0000269|PubMed:29618516, ECO:0000269|PubMed:9575137}. Nucleus
CC       {ECO:0000269|PubMed:29618516, ECO:0000269|PubMed:9575137}. Chromosome
CC       {ECO:0000269|PubMed:9575137}. Secreted, extracellular space,
CC       extracellular matrix {ECO:0000269|PubMed:12506096,
CC       ECO:0000269|PubMed:1683874}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q9WVJ6}. Mitochondrion
CC       {ECO:0000269|PubMed:24349085}. Note=Mainly localizes to the cytosol
CC       (PubMed:9575137). Present at much lower level in the nucleus and
CC       chromatin (PubMed:9575137). Also secreted via a non-classical secretion
CC       pathway to the extracellular matrix (PubMed:27270573).
CC       {ECO:0000269|PubMed:9575137, ECO:0000303|PubMed:27270573}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:17116873}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P21980-1; Sequence=Displayed;
CC       Name=2; Synonyms=TGase-S {ECO:0000303|PubMed:17116873};
CC         IsoId=P21980-2; Sequence=VSP_006411, VSP_006412;
CC       Name=3; Synonyms=TGH2;
CC         IsoId=P21980-3; Sequence=VSP_006413, VSP_006414;
CC   -!- INDUCTION: By retinoic acid. {ECO:0000269|PubMed:1358880}.
CC   -!- PTM: Disulfide bond formation inactivates the calcium-dependent
CC       acyltransferase activity (PubMed:20547769). Cys-370 can form disulfide
CC       bonds with both Cys-230 and Cys-371: formation of a disulfide bond
CC       between Cys-230 and Cys-370 facilitates formation of the disulfide
CC       between Cys-370 and Cys-371, which promotes inactivation of the
CC       acyltransferase activity (PubMed:20547769). May also form interchain
CC       disulfids between Cys-230 and Cys-370 (PubMed:25192068). Ca(2+)
CC       protects against disulfide bond formation and inactivation
CC       (PubMed:20547769). {ECO:0000269|PubMed:20547769,
CC       ECO:0000269|PubMed:25192068}.
CC   -!- PTM: Auto-transglutaminated: Forms covalent cross-links mediated by
CC       transglutaminase between Gln-633 and the epsilon-amino group of a
CC       lysine residue of itself or HMGB1, forming homopolymers and
CC       heteropolymers, respectively. {ECO:0000250|UniProtKB:P08587}.
CC   -!- PTM: S-nitrosylated, leading to inactivation of the acyltransferase
CC       activity. {ECO:0000250|UniProtKB:P21981}.
CC   -!- DISEASE: Note=TGM2 constitutes the major autoantigen in celiac disease,
CC       a multifactorial chronic disorder of the small intestine caused by
CC       intolerance to gluten (PubMed:9212111, PubMed:9623982). Celiac disease
CC       is characterized by immune-mediated enteropathy associated with failed
CC       intestinal absorption and malnutrition: intestinal inflammation is
CC       precipitated by ingestion of the protein gliadin, a component of wheat
CC       gluten in the diet (PubMed:9212111, PubMed:9623982). TGM2 is the main
CC       target for celiac disease-associated anti-endomysium autoantibodies
CC       (PubMed:9212111). It mediates its effect by catalyzing specific
CC       deamidation of gliadin; this deamidation creates an epitope that binds
CC       efficiently to HLA-DQ2 and is recognized by gut-derived T-cells
CC       (PubMed:9623982). {ECO:0000269|PubMed:9212111,
CC       ECO:0000269|PubMed:9623982}.
CC   -!- SIMILARITY: Belongs to the transglutaminase superfamily.
CC       Transglutaminase family. {ECO:0000305}.
CC   -!- CAUTION: Initial enzymatic assays were performed with a protein
CC       sequence containing a Gly residue instead of a Val at position 224:
CC       such protein displays lower Ca(2+)-binding affinity and reduced
CC       transglutaminase activity. {ECO:0000269|PubMed:1670766,
CC       ECO:0000269|PubMed:23941696}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tissue transglutaminase entry;
CC       URL="https://en.wikipedia.org/wiki/Tissue_transglutaminase";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgm2/";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Versatile - Issue 236 of May
CC       2021;
CC       URL="https://web.expasy.org/spotlight/back_issues/236/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55153; AAA63261.1; -; mRNA.
DR   EMBL; M98478; AAA36739.1; -; mRNA.
DR   EMBL; S81734; AAB36379.1; -; mRNA.
DR   EMBL; AY675221; AAT79353.1; -; mRNA.
DR   EMBL; AK291714; BAF84403.1; -; mRNA.
DR   EMBL; AK314618; BAG37184.1; -; mRNA.
DR   EMBL; DQ523828; ABF47109.1; -; Genomic_DNA.
DR   EMBL; AL031651; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW76040.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76042.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76044.1; -; Genomic_DNA.
DR   EMBL; BC003551; AAH03551.1; -; mRNA.
DR   EMBL; AL512703; CAC21649.1; -; mRNA.
DR   CCDS; CCDS13302.1; -. [P21980-1]
DR   PIR; A39045; A39045.
DR   PIR; A44302; A44302.
DR   PIR; S68092; S68092.
DR   RefSeq; NP_001310245.1; NM_001323316.1. [P21980-1]
DR   RefSeq; NP_004604.2; NM_004613.3. [P21980-1]
DR   RefSeq; NP_945189.1; NM_198951.2. [P21980-2]
DR   RefSeq; XP_011527330.1; XM_011529028.1. [P21980-1]
DR   PDB; 1KV3; X-ray; 2.80 A; A/B/C/D/E/F=1-687.
DR   PDB; 2Q3Z; X-ray; 2.00 A; A=1-687.
DR   PDB; 3LY6; X-ray; 3.14 A; A/B/C=1-687.
DR   PDB; 3S3J; X-ray; 2.25 A; A=2-687.
DR   PDB; 3S3P; X-ray; 2.50 A; A=2-687.
DR   PDB; 3S3S; X-ray; 2.30 A; A=2-687.
DR   PDB; 4PYG; X-ray; 2.80 A; A/B/E=1-687.
DR   PDB; 6A8P; X-ray; 2.54 A; A/B/C=1-687.
DR   PDB; 6KZB; X-ray; 3.35 A; A/B/C=1-687.
DR   PDBsum; 1KV3; -.
DR   PDBsum; 2Q3Z; -.
DR   PDBsum; 3LY6; -.
DR   PDBsum; 3S3J; -.
DR   PDBsum; 3S3P; -.
DR   PDBsum; 3S3S; -.
DR   PDBsum; 4PYG; -.
DR   PDBsum; 6A8P; -.
DR   PDBsum; 6KZB; -.
DR   AlphaFoldDB; P21980; -.
DR   SMR; P21980; -.
DR   BioGRID; 112910; 206.
DR   CORUM; P21980; -.
DR   DIP; DIP-33557N; -.
DR   IntAct; P21980; 79.
DR   MINT; P21980; -.
DR   STRING; 9606.ENSP00000355330; -.
DR   BindingDB; P21980; -.
DR   ChEMBL; CHEMBL2730; -.
DR   DrugBank; DB04315; Guanosine-5'-Diphosphate.
DR   DrugBank; DB11254; Hexylresorcinol.
DR   DrugBank; DB00130; L-Glutamine.
DR   GuidetoPHARMACOLOGY; 3015; -.
DR   GlyGen; P21980; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P21980; -.
DR   MetOSite; P21980; -.
DR   PhosphoSitePlus; P21980; -.
DR   SwissPalm; P21980; -.
DR   BioMuta; TGM2; -.
DR   DMDM; 20141877; -.
DR   CPTAC; CPTAC-1644; -.
DR   CPTAC; CPTAC-280; -.
DR   CPTAC; CPTAC-281; -.
DR   EPD; P21980; -.
DR   jPOST; P21980; -.
DR   MassIVE; P21980; -.
DR   MaxQB; P21980; -.
DR   PaxDb; P21980; -.
DR   PeptideAtlas; P21980; -.
DR   ProteomicsDB; 53947; -. [P21980-1]
DR   ProteomicsDB; 53948; -. [P21980-2]
DR   ProteomicsDB; 53949; -. [P21980-3]
DR   ABCD; P21980; 17 sequenced antibodies.
DR   Antibodypedia; 3611; 1367 antibodies from 47 providers.
DR   DNASU; 7052; -.
DR   Ensembl; ENST00000361475.7; ENSP00000355330.2; ENSG00000198959.12. [P21980-1]
DR   GeneID; 7052; -.
DR   KEGG; hsa:7052; -.
DR   MANE-Select; ENST00000361475.7; ENSP00000355330.2; NM_004613.4; NP_004604.2.
DR   AGR; HGNC:11778; -.
DR   CTD; 7052; -.
DR   DisGeNET; 7052; -.
DR   GeneCards; TGM2; -.
DR   HGNC; HGNC:11778; TGM2.
DR   HPA; ENSG00000198959; Tissue enhanced (cervix).
DR   MIM; 190196; gene.
DR   neXtProt; NX_P21980; -.
DR   OpenTargets; ENSG00000198959; -.
DR   PharmGKB; PA36491; -.
DR   VEuPathDB; HostDB:ENSG00000198959; -.
DR   eggNOG; ENOG502QUSX; Eukaryota.
DR   GeneTree; ENSGT01050000244866; -.
DR   HOGENOM; CLU_013435_1_0_1; -.
DR   InParanoid; P21980; -.
DR   OMA; CTVGPGE; -.
DR   OrthoDB; 5344745at2759; -.
DR   PhylomeDB; P21980; -.
DR   TreeFam; TF324278; -.
DR   BRENDA; 2.3.2.13; 2681.
DR   PathwayCommons; P21980; -.
DR   SignaLink; P21980; -.
DR   SIGNOR; P21980; -.
DR   BioGRID-ORCS; 7052; 14 hits in 1164 CRISPR screens.
DR   ChiTaRS; TGM2; human.
DR   EvolutionaryTrace; P21980; -.
DR   GeneWiki; Tissue_transglutaminase; -.
DR   GenomeRNAi; 7052; -.
DR   Pharos; P21980; Tchem.
DR   PRO; PR:P21980; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P21980; protein.
DR   Bgee; ENSG00000198959; Expressed in type B pancreatic cell and 172 other tissues.
DR   ExpressionAtlas; P21980; baseline and differential.
DR   Genevisible; P21980; HS.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:GOC.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000786; C:nucleosome; IDA:UniProt.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:CACAO.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0120297; F:histone dopaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0120295; F:histone serotonyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0120299; F:peptide histaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0120298; F:peptide noradrenalinyltransferase activity; IEA:RHEA.
DR   GO; GO:0003810; F:protein-glutamine gamma-glutamyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0050568; F:protein-glutamine glutaminase activity; IDA:UniProtKB.
DR   GO; GO:0043277; P:apoptotic cell clearance; IDA:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0071314; P:cellular response to cocaine; IDA:UniProtKB.
DR   GO; GO:1903351; P:cellular response to dopamine; IDA:UniProtKB.
DR   GO; GO:1904015; P:cellular response to serotonin; IDA:UniProtKB.
DR   GO; GO:0014046; P:dopamine secretion; IDA:UniProt.
DR   GO; GO:0010467; P:gene expression; IDA:UniProt.
DR   GO; GO:0032471; P:negative regulation of endoplasmic reticulum calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0051561; P:positive regulation of mitochondrial calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; IDA:UniProtKB.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; ISS:UniProtKB.
DR   GO; GO:0018277; P:protein deamination; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:2000425; P:regulation of apoptotic cell clearance; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0060662; P:salivary gland cavitation; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 3.
DR   Gene3D; 3.90.260.10; Transglutaminase-like; 1.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR002931; Transglutaminase-like.
DR   InterPro; IPR036985; Transglutaminase-like_sf.
DR   InterPro; IPR023608; Transglutaminase_animal.
DR   InterPro; IPR013808; Transglutaminase_AS.
DR   InterPro; IPR008958; Transglutaminase_C.
DR   InterPro; IPR036238; Transglutaminase_C_sf.
DR   InterPro; IPR001102; Transglutaminase_N.
DR   PANTHER; PTHR11590; PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE; 1.
DR   PANTHER; PTHR11590:SF6; PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE 2; 1.
DR   Pfam; PF00927; Transglut_C; 2.
DR   Pfam; PF01841; Transglut_core; 1.
DR   Pfam; PF00868; Transglut_N; 1.
DR   PIRSF; PIRSF000459; TGM_EBP42; 1.
DR   SMART; SM00460; TGc; 1.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF49309; Transglutaminase, two C-terminal domains; 2.
DR   PROSITE; PS00547; TRANSGLUTAMINASES; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Alternative splicing; Calcium;
KW   Cell membrane; Chromosome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; Extracellular matrix; GTP-binding; Hydrolase;
KW   Isopeptide bond; Membrane; Metal-binding; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Protease; Reference proteome;
KW   S-nitrosylation; Secreted; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.10, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..687
FT                   /note="Protein-glutamine gamma-glutamyltransferase 2"
FT                   /id="PRO_0000213707"
FT   ACT_SITE        277
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10024,
FT                   ECO:0000305|PubMed:7649299, ECO:0000305|PubMed:8943303"
FT   ACT_SITE        335
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10024"
FT   ACT_SITE        358
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10024"
FT   BINDING         398
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P00488"
FT   BINDING         400
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P00488"
FT   BINDING         437
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305|PubMed:31991788"
FT   BINDING         447
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P00488"
FT   BINDING         452
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P00488"
FT   BINDING         476..483
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:25192068,
FT                   ECO:0000269|PubMed:30321187, ECO:0000269|PubMed:31991788,
FT                   ECO:0000305|PubMed:11867708, ECO:0000305|PubMed:20450932,
FT                   ECO:0007744|PDB:1KV3, ECO:0007744|PDB:3LY6,
FT                   ECO:0007744|PDB:4PYG, ECO:0007744|PDB:6A8P,
FT                   ECO:0007744|PDB:6KZB"
FT   BINDING         539
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000305|PubMed:31991788"
FT   BINDING         580..583
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000269|PubMed:25192068,
FT                   ECO:0000269|PubMed:30321187, ECO:0000269|PubMed:31991788,
FT                   ECO:0000305|PubMed:11867708, ECO:0000305|PubMed:20450932,
FT                   ECO:0007744|PDB:1KV3, ECO:0007744|PDB:3LY6,
FT                   ECO:0007744|PDB:4PYG, ECO:0007744|PDB:6A8P,
FT                   ECO:0007744|PDB:6KZB"
FT   SITE            516
FT                   /note="Important for catalytic activity"
FT                   /evidence="ECO:0000250|UniProtKB:P52181"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.10, ECO:0007744|PubMed:22814378"
FT   MOD_RES         60
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         468
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P21981"
FT   DISULFID        230..370
FT                   /note="Alternate"
FT                   /evidence="ECO:0000269|PubMed:20450932,
FT                   ECO:0000269|PubMed:20547769, ECO:0000269|PubMed:25192068"
FT   DISULFID        370..371
FT                   /note="Alternate"
FT                   /evidence="ECO:0000269|PubMed:20547769"
FT   CROSSLNK        633
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P08587"
FT   VAR_SEQ         287..349
FT                   /note="VLRCLGIPTRVVTNYNSAHDQNSNLLIEYFRNEFGEIQGDKSEMIWNFHCWV
FT                   ESWMTRPDLQP -> GELHAGMWVMSPGRGHEEHWSRNQDIPALVLPPATNTLNALCGL
FT                   EPVTTLSGPLSNSHPSSGC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8611626"
FT                   /id="VSP_006413"
FT   VAR_SEQ         350..687
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8611626"
FT                   /id="VSP_006414"
FT   VAR_SEQ         539..548
FT                   /note="EKSVPLCILY -> GKALCSWSIC (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1358880,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006411"
FT   VAR_SEQ         549..687
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1358880,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006412"
FT   VARIANT         76
FT                   /note="R -> H (in dbSNP:rs41274720)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_052553"
FT   VARIANT         214
FT                   /note="R -> H (in dbSNP:rs45530133)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_055357"
FT   VARIANT         324
FT                   /note="Q -> R (in dbSNP:rs45567334)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_055358"
FT   VARIANT         330
FT                   /note="M -> R (in patients with early-onset diabetes type
FT                   2; unknown pathological significance; dbSNP:rs141603506)"
FT                   /evidence="ECO:0000269|PubMed:17939176"
FT                   /id="VAR_037998"
FT   VARIANT         331
FT                   /note="I -> N (in patients with early-onset diabetes type
FT                   2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:17939176"
FT                   /id="VAR_037999"
FT   VARIANT         436
FT                   /note="R -> W (in dbSNP:rs45629036)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_055359"
FT   VARIANT         536
FT                   /note="P -> S (in dbSNP:rs45556333)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_052554"
FT   VARIANT         660
FT                   /note="G -> V (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036554"
FT   MUTAGEN         171
FT                   /note="S->E: Abolishes GTP-binding and transglutaminase
FT                   activities. Does not have cytotoxic activity when
FT                   overexpressed."
FT                   /evidence="ECO:0000269|PubMed:17116873"
FT   MUTAGEN         180
FT                   /note="W->F: Abolished isopeptidase activity and reduced
FT                   transamidase activity."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         180
FT                   /note="W->L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         224
FT                   /note="V->G: Displays lower Ca(2+)-binding affinity and
FT                   reduced transglutaminase activity."
FT                   /evidence="ECO:0000269|PubMed:23941696"
FT   MUTAGEN         230
FT                   /note="C->A: Does not affect the protein-glutamine
FT                   deamidase activity."
FT                   /evidence="ECO:0000269|PubMed:20547769"
FT   MUTAGEN         241
FT                   /note="W->F,L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         277
FT                   /note="C->S: Abolished protein-glutamine
FT                   gamma-glutamyltransferase activity without affecting
FT                   alpha-1 adrenergic receptor signaling. Abolished
FT                   isopeptidase activity."
FT                   /evidence="ECO:0000269|PubMed:24349085,
FT                   ECO:0000269|PubMed:26250429, ECO:0000269|PubMed:7649299,
FT                   ECO:0000269|PubMed:8943303"
FT   MUTAGEN         277
FT                   /note="C->V: Dominant negative mutant. Abolishes WDR54
FT                   cross-linking."
FT                   /evidence="ECO:0000269|PubMed:30458214"
FT   MUTAGEN         278
FT                   /note="W->F: In TG2-T; strongly reduced isopeptidase
FT                   activity without affecting the transamidase activity."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         278
FT                   /note="W->L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         332
FT                   /note="W->F: In TG2-I; strongly reduced transamidase
FT                   activity without affecting the isopeptidase activity."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         332
FT                   /note="W->L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         334
FT                   /note="F->L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         337
FT                   /note="W->F: Reduced isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         337
FT                   /note="W->L: Abolished isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         370
FT                   /note="C->A: Impaired substrate recognition for the
FT                   protein-glutamine deamidase activity."
FT                   /evidence="ECO:0000269|PubMed:20547769"
FT   MUTAGEN         371
FT                   /note="C->A: Impaired substrate recognition for the
FT                   protein-glutamine deamidase activity."
FT                   /evidence="ECO:0000269|PubMed:20547769"
FT   MUTAGEN         437
FT                   /note="E->R: Impaired Ca(2+)-binding leading to reduced
FT                   transglutaminase activity."
FT                   /evidence="ECO:0000269|PubMed:31991788"
FT   MUTAGEN         516
FT                   /note="Y->L: No effect on isopeptidase and transamidase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:26250429"
FT   MUTAGEN         539
FT                   /note="E->R: Impaired Ca(2+)-binding leading to reduced
FT                   transglutaminase activity."
FT                   /evidence="ECO:0000269|PubMed:31991788"
FT   MUTAGEN         665..672
FT                   /note="VVNFESDK->IASMSSDS: Substitution with F13A1
FT                   sequence. Abolished interaction with phospholipase C and
FT                   ability to promote alpha-1 adrenergic receptor signaling."
FT                   /evidence="ECO:0000269|PubMed:7592956"
FT   CONFLICT        51
FT                   /note="E -> Q (in Ref. 1; AAA63261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        186
FT                   /note="E -> Q (in Ref. 1; AAA63261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="V -> G (in Ref. 1; AAA63261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        533
FT                   /note="N -> T (in Ref. 1; AAA63261)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        655
FT                   /note="L -> V (in Ref. 1; AAA63261)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..11
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           14..20
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           24..26
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          28..30
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          32..34
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          39..48
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            52..54
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          55..66
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            69..72
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          73..79
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:4PYG"
FT   STRAND          89..95
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          97..105
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          113..123
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          126..138
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           153..159
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          164..170
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          172..181
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           189..198
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           201..205
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           207..213
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           217..226
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            227..229
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            231..234
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          235..239
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            251..253
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          255..257
FT                   /evidence="ECO:0007829|PDB:4PYG"
FT   HELIX           258..266
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            267..269
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          272..275
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           277..291
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          295..304
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          306..309
FT                   /evidence="ECO:0007829|PDB:1KV3"
FT   HELIX           311..317
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          332..342
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          347..350
FT                   /evidence="ECO:0007829|PDB:3LY6"
FT   STRAND          353..357
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          365..369
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           376..380
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            387..389
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           390..397
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          400..404
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          412..414
FT                   /evidence="ECO:0007829|PDB:6A8P"
FT   STRAND          419..429
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          433..438
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           440..443
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          447..449
FT                   /evidence="ECO:0007829|PDB:3LY6"
FT   HELIX           450..460
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            468..471
FT                   /evidence="ECO:0007829|PDB:3LY6"
FT   STRAND          473..478
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          489..497
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          499..501
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          503..514
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          520..534
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          538..546
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   HELIX           548..551
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            552..554
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          560..569
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            570..573
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          574..583
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          590..595
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          598..601
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          603..610
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          613..615
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          619..625
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   TURN            627..629
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          634..638
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          647..654
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          658..660
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          662..669
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          671..673
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   STRAND          676..682
FT                   /evidence="ECO:0007829|PDB:2Q3Z"
FT   MUTAGEN         P21980-2:277
FT                   /note="C->V: Abolished protein-glutamine
FT                   gamma-glutamyltransferase activity without affecting
FT                   cytotoxic activity."
FT                   /evidence="ECO:0000269|PubMed:17116873"
SQ   SEQUENCE   687 AA;  77329 MW;  7DA33FF335DE7B37 CRC64;
     MAEELVLERC DLELETNGRD HHTADLCREK LVVRRGQPFW LTLHFEGRNY EASVDSLTFS
     VVTGPAPSQE AGTKARFPLR DAVEEGDWTA TVVDQQDCTL SLQLTTPANA PIGLYRLSLE
     ASTGYQGSSF VLGHFILLFN AWCPADAVYL DSEEERQEYV LTQQGFIYQG SAKFIKNIPW
     NFGQFEDGIL DICLILLDVN PKFLKNAGRD CSRRSSPVYV GRVVSGMVNC NDDQGVLLGR
     WDNNYGDGVS PMSWIGSVDI LRRWKNHGCQ RVKYGQCWVF AAVACTVLRC LGIPTRVVTN
     YNSAHDQNSN LLIEYFRNEF GEIQGDKSEM IWNFHCWVES WMTRPDLQPG YEGWQALDPT
     PQEKSEGTYC CGPVPVRAIK EGDLSTKYDA PFVFAEVNAD VVDWIQQDDG SVHKSINRSL
     IVGLKISTKS VGRDEREDIT HTYKYPEGSS EEREAFTRAN HLNKLAEKEE TGMAMRIRVG
     QSMNMGSDFD VFAHITNNTA EEYVCRLLLC ARTVSYNGIL GPECGTKYLL NLNLEPFSEK
     SVPLCILYEK YRDCLTESNL IKVRALLVEP VINSYLLAER DLYLENPEIK IRILGEPKQK
     RKLVAEVSLQ NPLPVALEGC TFTVEGAGLT EEQKTVEIPD PVEAGEEVKV RMDLLPLHMG
     LHKLVVNFES DKLKAVKGFR NVIIGPA
//
